Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects
NCT04939662
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
25
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer
Interventions
DRUG:
Olaparib+Bevacizumab to SCLC patients
Sponsor
Se-Hoon Lee
Collaborators
[object Object]
[object Object]